Leadership & Pay ·
On June 23, 2026, Keros Therapeutics appointed Anne Prener, M.D., Ph.D., as a Class III director, effective July 1…
KROSKeros Therapeutics, Inc.
On June 23, 2026, Keros Therapeutics appointed Anne Prener, M.D., Ph.D., as a Class III director, effective July 1, 2026, with a term expiring at the 2029 annual meeting. Dr. Prener will receive a $41,500 annual cash retainer, an initial stock option grant and initial RSU grant each with a fair value of $150,000, and annual option and RSU grants each valued at $75,000. The company operates in the biopharmaceutical industry and develops therapies for hematologic and musculoskeletal disorders.